Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 15/20 | 0.61 |
| ▸ | PGR | P06401 | 4/20 | 0.61 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2859774 | 0.76 | AR (1.00) | ARPGRNR3C2 | |
| SCHEMBL9426317 | 0.68 | ALDH1A1 (0.50) | ARPGRNR3C2MEN1KMT2A | |
| SCHEMBL5231375 | 0.67 | AR (0.75) | ARPGRNR3C2 | |
| SCHEMBL14409343 | 0.66 | AR (0.69) | ARPGRNR3C2 | |
| SCHEMBL9132215 | 0.65 | CYP1A2 (0.66) | ARPGRMEN1KMT2ACYP1A2 | |
| SCHEMBL19236106 | 0.65 | AR (1.00) | ARPGRNR3C2 | |
| SCHEMBL9131747 | 0.64 | KCNA3 (0.60) | MEN1KMT2ACYP1A2CRHBPCASP1 | |
| SCHEMBL9135495 | 0.64 | CSNK2A2 (0.69) | CYP1A2ALDH1A1HPGDHSD17B10CYP1A1 | |
| SCHEMBL10840425 | 0.63 | AR (0.45) | ARPGRNR3C2 | |
| SCHEMBL9133816 | 0.63 | ALDH1A1 (0.47) | ARPGRNR3C2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210678-A1 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2010-08-19 | — | — | US | claimed |
| US-20070293528-A9 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | claimed |
| US-20060128740-A1 | Tricyclic androgen receptor modulator compounds and methods | ZHI LIN | 2006-06-15 | — | — | US | claimed |
| US-20020183346-A1 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2002-12-05 | — | — | US | claimed |
| US-20100210678-A1 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2010-08-19 | — | — | US | disclosed |
| US-7727980-B2 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070293528-A9 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20060128740-A1 | Tricyclic androgen receptor modulator compounds and methods | ZHI LIN | 2006-06-15 | — | — | US | disclosed |
| US-7026484-B2 | For therapy of cancer | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2006-04-11 | — | — | US | disclosed |
| EP-1363909-A2 | TRICYCLIC ANDROGEN RECEPTOR MODULATOR COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20020183346-A1 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2002-12-05 | — | — | US | disclosed |
| WO-2002066475-A2 | TRICYCLIC ANDROGEN RECEPTOR MODULATOR COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183346-A1 | Tricyclic androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | AR 1/4885PGR 42/4885NR3C2 14/4885 |
| US-20070293528-A9 | Tricyclic androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | AR 1/4885PGR 42/4885NR3C2 14/4885 |
| US-20100210678-A1 | Tricyclic androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | AR 1/4885PGR 46/4885NR3C2 14/4885 |
| US-20060128740-A1 | Tricyclic androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | AR 1/4885PGR 42/4885NR3C2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.